by The AIS market consists of various medical devices and medication used in the treatment of acute ischemic stroke. A stroke or cerebrovascular accident is caused by interruption of blood supply to the brain, usually because of a clot or blockage in a blood vessel leading to the brain. AIS is the most common type of stroke caused by a clot or blockage in an artery supplying blood to the brain. There is a high unmet clinical need for improved therapies to reduce AIS disability and mortality.
The global AIS market size is estimated to be valued at US$ 10,612.22 billion in 2024 and is expected to exhibit a CAGR of 18% over the forecast period of 2024 to 2031.
Key Takeaways
Key players operating in the AIS market are F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio and Athersys Inc. These key players are involved in developing and commercializing drugs and devices for AIS treatment. There is a significant scope for developing advanced thrombolytic agents, devices and neuro-protective drugs with reduced risk and increased therapeutic time windows. The rising research on stem cell therapy and neurovascular regeneration provides a key opportunity in the global AIS market. Factors such as increasing healthcare expenditure, regulatory approvals and rising geriatric population globally are further expected to boost the market expansion during the forecast period.
Market drivers
The major driver propelling the growth of Acute Ischemic Stroke Market Size is the rising prevalence of stroke globally. According to WHO estimates, 15 million people suffer a stroke worldwide each year out of which 5 million die and another 5 million are permanently disabled. Developing countries are facing the largest increase in prevalence of stroke. Growing elderly population susceptibility to AIS is another key factor augmenting the market growth. Increasing awareness about early diagnosis and treatment of AIS and government support through healthcare funding are further contributing to the market growth.
PEST Analysis
Political: Regulations around AIS treatment are becoming more lenient with approval of new drugs, which is encouraging pharmaceutical companies to invest more in R&D. However, pricing pressures and drug price negotiations still impact profits.
Economic: As incomes rise globally, healthcare expenditures are also increasing allowing for more treatments of AIS. However, economic slowdowns can threaten sales growth of companies.
Social: As lifestyle diseases rise and ageing population grows, incidence of AIS is increasing imposing higher social costs. Raising awareness about risk factors and early signs of stroke is crucial.
Technological: companies are investing in novel drug delivery systems, stem cell therapies and genomics to develop more effective and personalized AIS treatments. Wearable tech and remote patient monitoring tools help manage post-stroke care.
The market in terms of value is most concentrated in North America and Europe due to higher healthcare expenditures, stringent reimbursement for innovative drugs, and growing geriatric population in these regions. However, Asia Pacific region is poised to be the fastest growing market for AIS due to rising instances of lifestyle diseases, improving access to healthcare facilities and growing medical tourism. China and India specifically are emerging as lucrative markets.
The concentration of treatment and hospitals in large metropolitan areas allows for easier access to specialized stroke care. However, risk of AIS and access to treatment remains a challenge in remote and rural regions. Telestroke and mobile stroke units are helping bridge these geographic gaps and expand reach of acute stroke management to wider populations.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
